Search results
Found 37950 matches for
Exscientia, the leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD).
François Nosten: Between research and humanitarian
Malaria
Combining healthcare and research allow Professor Nosten to implement a new treatment regimen as soon as the results from clinical trials are available, which is beneficial to patients and highly rewarding for researchers.